We are live on ! Find out more
NXTC icon

NextCure

43 hedge funds and large institutions have $19.6M invested in NextCure in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.45% less ownership

Funds ownership: 48.2% → 47.75% (-0.45%)

7% less capital inflows, than outflows

Capital inflows: $1.65M | Capital outflows: $1.78M

4% less funds holding

Funds holding: 45 → 43 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Holders
43
Holders Change
-2
Holders Change %
-4.44%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
13
Closed
7
Calls
$231​K
Puts
–
Net Calls
+$231​K
Net Calls Change
+$75​K

NXTC Hedge Fund Activity: Q1 2023 in Review

43 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2023, worth a combined $19.6M — up 4% from $18.9M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NXTC and 5 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 6 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $642K. The largest seller was Cardiff Park Advisors, exiting entirely with an estimated $369K sold.

  • 43 institutional investors held NextCure (NXTC) as of Q1 2023, down from 45 in Q4 2022.
  • Funds reported $19.6M of NextCure stock for Q1 2023, up 4% quarter-over-quarter.
  • 5 funds opened new NextCure positions in Q1 2023 and 7 closed out, a net change of -2 holders.
  • The largest NextCure buyer in Q1 2023 was Tang Capital Management, an estimated $642K added.
  • The largest NextCure seller in Q1 2023 was Cardiff Park Advisors, an estimated $369K sold.

Based on aggregated 13F filings for Q1 2023.